The Future of Immunotherapy in Low-Grade Serous Ovarian Cancer Treatment

Video

The panel explains how low-grade serous ovarian cancer differs from high-grade, and if an immunotherapy approach is appropriate for treatment.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Related Content
Investigators of the OVATION-2 trial assessed IMNN-001, a novel IL-2 gene therapy, in patients with newly diagnosed epithelial ovarian cancer.

PFS, OS Numerically Improve Via IMNN-001 Combo in Epithelial Ovarian Cancer

Chris Ryan
June 4th 2025
Article

Investigators of the OVATION-2 trial assessed IMNN-001, a novel IL-2 gene therapy, in patients with newly diagnosed epithelial ovarian cancer.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Data from the ROSELLA trial may support relacorilant plus nab-paclitaxel as a new standard in this ovarian cancer population.

Relacorilant and Nab-Paclitaxel Significantly Extend PFS in Ovarian Cancer

Gina Mauro
June 2nd 2025
Article

Data from the ROSELLA trial may support relacorilant plus nab-paclitaxel as a new standard in this ovarian cancer population.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Less radical surgery did not come at the expense of postoperative metrics, including 30-day readmissions, surgical findings, or receipt of adjuvant therapy.

Simple vs Radical Hysterectomy Shows Comparable Survival in Cervical Cancer

Roman Fabbricatore
May 27th 2025
Article

Less radical surgery did not come at the expense of postoperative metrics, including 30-day readmissions, surgical findings, or receipt of adjuvant therapy.

The safety profile of pembrolizumab in the KEYNOTE-B96 study was comparable with prior reports of the agent, and investigators observed no new safety signals.

Pembrolizumab Combo Extends PFS in Platinum-Resistant Ovarian Cancer

Russ Conroy
May 15th 2025
Article

Data from the KEYNOTE-B96 trial also show a significant overall survival improvement with pembrolizumab-based treatment in PD-L1–positive disease.